StockData

Novavax Inc (NVAX) stock

NVAXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 4/30
$7.96−0.10 (-1.24%)

Close on Nov 17, 2026Market cap $1.31BP/E –Yield –

Novavax total assets

Total assets on the balance sheet at the end of each period.

Novavax's total assets was $955.58M at Jun 30, 2026. For fiscal 2025 it was $1.18B, down 24.6% from the year before. Over ten years it grew 11.8% a year on average. The highest annual figure on record is $2.58B in fiscal 2021.

Annual total assets

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.18B-24.6%
FY2024Dec 31, 2024$1.56B-13.2%
FY2023Dec 31, 2023$1.80B-20.4%
FY2022Dec 31, 2022$2.26B-12.3%
FY2021Dec 31, 2021$2.58B+62.8%
FY2020Dec 31, 2020$1.58B+815.0%
FY2019Dec 31, 2019$172.96M-16.8%
FY2018Dec 31, 2018$207.98M-31.2%
FY2017Dec 31, 2017$302.49M-23.3%
FY2016Dec 31, 2016$394.30M+2.1%
FY2015Dec 31, 2015$386.04M+39.9%
FY2014Dec 31, 2014$276.00M+17.4%
FY2013Dec 31, 2013$235.13M+129.7%
FY2012Dec 31, 2012$102.35M+53.7%
FY2011Dec 31, 2011$66.58M-11.0%
FY2010Dec 31, 2010$74.84M–

Quarterly total assets

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$955.58M-28.5%
Q1 FY2026Mar 31, 2026$1.04B-19.3%
Q4 FY2025Dec 31, 2025$1.18B-24.6%
Q3 FY2025Sep 30, 2025$1.18B-31.1%
Q2 FY2025Jun 30, 2025$1.34B-26.5%
Q1 FY2025Mar 31, 2025$1.29B-4.5%
Q4 FY2024Dec 31, 2024$1.56B-13.2%
Q3 FY2024Sep 30, 2024$1.71B+3.3%
Q2 FY2024Jun 30, 2024$1.82B+7.9%
Q1 FY2024Mar 31, 2024$1.35B-12.3%
Q4 FY2023Dec 31, 2023$1.80B-20.4%
Q3 FY2023Sep 30, 2023$1.66B-26.9%
Q2 FY2023Jun 30, 2023$1.69B-35.8%
Q1 FY2023Mar 31, 2023$1.54B-45.6%
Q4 FY2022Dec 31, 2022$2.26B-12.3%
Q3 FY2022Sep 30, 2022$2.27B-11.6%
Q2 FY2022Jun 30, 2022$2.62B-4.6%
Q1 FY2022Mar 31, 2022$2.83B+8.7%
Q4 FY2021Dec 31, 2021$2.58B+62.8%
Q3 FY2021Sep 30, 2021$2.57B+171.8%
Q2 FY2021Jun 30, 2021$2.75B+194.9%
Q1 FY2021Mar 31, 2021$2.61B+695.1%
Q4 FY2020Dec 31, 2020$1.58B+815.0%
Q3 FY2020Sep 30, 2020$944.02M+472.8%
Q2 FY2020Jun 30, 2020$932.23M+392.2%
Q1 FY2020Mar 31, 2020$328.07M+48.2%
Q4 FY2019Dec 31, 2019$172.96M-16.8%
Q3 FY2019Sep 30, 2019$164.81M-34.2%
Q2 FY2019Jun 30, 2019$189.39M-33.7%
Q1 FY2019Mar 31, 2019$221.32M-19.8%
Q4 FY2018Dec 31, 2018$207.98M-31.2%
Q3 FY2018Sep 30, 2018$250.48M-25.0%
Q2 FY2018Jun 30, 2018$285.81M-19.7%
Q1 FY2018Mar 31, 2018$276.07M-23.6%
Q4 FY2017Dec 31, 2017$302.49M-23.3%
Q3 FY2017Sep 30, 2017$334.08M-27.3%
Q2 FY2017Jun 30, 2017$355.71M–
Q1 FY2017Mar 31, 2017$361.50M–
Q4 FY2016Dec 31, 2016$394.30M–
Q3 FY2016Sep 30, 2016$459.63M–

More Novavax figures

See a number that looks wrong?